It is stable and widely available, but the body must convert it into active forms before use
C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., Grinspoon, S
The design bet behind a GLP-1/glucagon dual agonist is that GLP-1s insulinotropic, appetite-suppressing, glucose-lowering effects can be used to offset the hyperglycemic tendency of glucagon, while glucagons thermogenic and hepatic-lipid effects add weight-loss and liver-directed benefits that GLP-1 alone does not deliver
What Is TB500
Fletcher and colleagues (J Pharmacol Exp Ther, 2021) profiled it across 25 endpoints against selective and non-selective comparators including pramlintide and salmon calcitonin, and cryo-EM structures of cagrilintide bound to CTR and the amylin receptors were reported by Cao and colleagues (Nat Commun, 2025)